ReviewTherapeutic advances in medical oncology2020
Optimal treatment strategy for metastatic melanoma patients harboring
Review in Therapeutic advances in medical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05501912 (A Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Cancer Activity of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Cancer Activity of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors
Who cites it
22 citing papers in PubMed, 42 citations in OpenAlex.
- Dysregulation of the PATZ1/CTCF Balance Silences ZBTB20 to Drive Melanoma Progression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Pembrolizumab for high TMB castration-resistant prostate cancer: A precision medicine case report.International cancer conference journal · 2026Article
- Inter-Relationship Between Melanoma Vemurafenib Tolerance Thresholds and Metabolic Pathway Choice.Cells · 2025Article
- An Optimized CRISPR/Cas12a Assay to Facilitate the BRAF V600E Mutation Detection.Journal of clinical laboratory analysis · 2024Article
- Targeted Sequencing of HER2-Positive Breast Cancer Mutations Revealed a Potential Association between PIK3CA and Trastuzumab Resistance.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- An updated literature on BRAF inhibitors (2018-2023).Molecular diversity · 2024Review
- Efficacy and safety of guttiferone E in melanoma-bearing mice.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Mechanisms of Melanoma Progression and Treatment Resistance: Role of Cancer Stem-like Cells.Cancers · 2024Review
- Construction of a novel prognostic model in skin cutaneous melanoma based on chemokines-related gene signature.Scientific reports · 2023Article
- Phenolic Compounds Contribution to Portuguese Propolis Anti-Melanoma Activity.Molecules (Basel, Switzerland) · 2023Article
- Genomics and Epigenomics in the Molecular Biology of Melanoma-A Prerequisite for Biomarkers Studies.International journal of molecular sciences · 2022Review
- Retrospective review of outcomes associated with metastatic melanoma patients treated with 1st-line BRAF-targeted therapy.Pigment cell & melanoma research · 2022Article
- Low doses of niclosamide and quinacrine combination yields synergistic effect in melanoma via activating autophagy-mediated p53-dependent apoptosis.Translational oncology · 2022Article
- Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR.Cancers · 2022Article
- Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients-Real-World Evidence.Journal of clinical medicine · 2022Article
- Upregulation of the novel lncRNA U731166 is associated with migration, invasion and vemurafenib resistance in melanoma.Journal of cellular and molecular medicine · 2022Article
- Review
- The human melanoma proteome atlas-Defining the molecular pathology.Clinical and translational medicine · 2021Article
- Current Landscape and Open Questions on Adjuvant Therapies in Melanoma.Dermatology practical & conceptual · 2021Review
- BRAF Gene and Melanoma: Back to the Future.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.